



1

WE CLAIM:

- 1. A non-irritating anti-viral lotioned tissue product having applied to at least one surface thereof an anti-viral lotion composition comprising:

 a virucidal effective amount of at least one anti-viral organic acid;
 a topical delivery system including at least one polyester.
- 2. The lotioned tissue product of claim 1, wherein said lotion composition comprises from about 1% to about 25% of said anti-viral organic acid.
- 3. The lotioned tissue product of claim 2, wherein said at least one anti-viral organic acid comprises at least one member from the group consisting of carboxylic acids having the structure R-COOH, wherein R is a C₁-C₆ alkyl; C₁-C₆ alkyl carboxy; C₁-C₆ alkyl carboxyhydroxy; C₁-C₆ alkyl carboxy halo; C₁-C₆ alkyl dicarboxyhydroxy; C₁-C₆ alkenyl; C₁-C₆ alkenyl carboxy; C₁-C₆ alkenyl phenyl; or substituted phenyl radical.
- 4. The lotioned tissue product of claim 3, wherein one or more hydrogen atoms of R is substituted with a functional group selected from the group consisting of halogen atoms, hydroxyl groups, amino groups, thiol groups, nitro groups, and cyano groups.
- 5. The lotioned tissue product of claim 3, wherein said at least one anti-viral acid is selected from the group consisting of citric acid, malic acid, adipic acid, glutaric acid, succinic acid, and mixtures thereof.
- 6. The lotioned tissue product of claim 2, wherein said at least one polyester comprises a hydroxy-functional polyester diol.
- 7. The lotioned tissue product of claim 6, wherein said at least one polyester comprises trimethylpentanediol/adipic acid copolymer.

20



- 8. The lotioned tissue product of claim 2, wherein said at least one polyester comprises a fatty alkyl capped complex polyester.
- 9. The lotioned tissue product of claim 8, wherein said at least one polyester comprises trimethylpentanediol/adipic isononanoic acid copolymer
- 10. The lotioned tissue product of claim 1, wherein the lotion composition further comprises a surfactant.
- 11. A lotioned tissue product having applied to at least one surface thereof an anti-viral lotion composition comprising:

about 1% to about 25% of at least one anti-viral organic acid; about 5% to about 25% of an emollient including at least one polyester; and

a cationic surfactant.


- 12. The lotioned tissue product of claim 11, wherein said emollient comprises at least one polyester from the group consisting of fatty alkyl capped complex polyesters, hydroxy-functional polyester diols, and mixtures thereof.
- 13. The lotioned tissue product of claim 11, wherein said cationic surfactant comprises a quaternary ammonium compound.
- 14. A non-irritating, anti-viral lotion composition comprising:
 a virucidal effective amount of at least one anti-viral organic acid;
 and

a topical delivery system including at least one polyester.


- 15. The lotion composition of claim 14, wherein said lotion composition comprises from about 1% to about 25% of said anti-viral organic acid.
- 16. The lotion composition of claim 15, wherein said at least one antiviral organic acid comprises at least one member from the group consisting of

20





- 17. The lotion composition of claim 16, wherein one or more hydrogen atoms of R is substituted with a functional group selected from the group consisting of halogen atoms, hydroxyl groups, amino groups, thiol groups, nitro groups, and cyano groups.
- 18. The lotion composition of claim 16, wherein said at least one antiviral acid is selected from the group consisting of citric acid, malic acid, adipic acid, glutaric acid, succinic acid, and mixtures thereof.
- 19. The lotion composition of claim 15, wherein said at least one polyester comprises a hydroxy-functional polyester diol.
- 20. The lotion composition of claim 19, wherein said at least one polyester comprises trimethylpentanediol/adipic acid copolymer.
- 21. The lotion composition of claim 15, wherein said at least one polyester comprises a fatty alkyl capped complex polyester.
- The lotion composition of claim 21, wherein said at least one 22. polyester comprises trimethylpentanediol/adipic isononanoic acid copolymer
- 23. The lotion composition of claim 14, wherein the lotion composition further comprises a surfactant.
- 24. The lotion composition of claim 23, wherein said surfactant comprises a cationic surfactant.
 - 25. A anti-viral lotion composition comprising: about 1% to about 25% of at least one anti-viral organic acid;



a cationic surfactant.

- 26. The lotion composition of claim 25, wherein said emollient comprises at least one polyester from the group consisting of fatty alkyl capped complex polyesters, hydroxy-functional polyester diols, and mixtures thereof.
- 27. The lotion composition of claim 26, wherein said cationic surfactant comprises a quaternary ammonium compound.
- 28. A method of inhibiting the transfer of a viral infection comprising:

 providing anti-viral lotion tissue product having applied to at least
 one surface thereof an anti-viral lotion composition comprising a virucidal
 effective amount of at least one anti-viral organic acid and a topical delivery
 system including at least one polyester;

contacting a fluid containing at least one virus with said anti-viral tissue product; and

absorbing said fluid within said absorbent article to contact the fluid with said anti-viral lotion composition.

- 29. The method of claim 28, further comprising:
 transferring a portion of the lotion composition to the user of the tissue product.
- 30. The method of claim 28, wherein said at least one polyester comprises a hydroxy-functional polyester diol.
- 31. The method of claim 28, wherein said at least one polyester comprises a fatty alkyl capped complex polyester.
- 32. A method of making an anti-viral tissue product comprising:

 heating a composition comprising an a virucidal effective amount of
 at least one anti-viral organic acid at least one polyester, at least one oil and at

20





least one wax to a temperature above the melting point of the composition, causing said composition to melt, said composition having a melting point of from about 30°C to about 70°C;

uniformly applying the melted composition to at least one surface of a tissue web in spaced-apart deposits; and

resolidifying the deposits of the melted composition.

- 33. The method of claim 32 wherein the heated composition is applied to the tissue web with a gravure printer.
- 34. The method of claim 32 wherein the tissue web is cooled before or after the deposits of the coating composition are applied in order to accelerate solidification of the deposits.
 - 35. The method of claim 32 wherein the tissue product is a facial tissue.